AMNEAL PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.76 USD | +8.86% |
|
+15.16% | +11.37% |
| 05-03 | Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating | MT |
| 05-03 | Drugmaker Amneal agrees to $270 million U.S. opioid settlement | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Companyâs Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segmentâs portfolio includes central nervous system disorders (Parkinsonâs disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Companyâs AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
Sector
Pharmaceuticals
Calendar
04/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
6.76
USD
Average target price
7.312
USD
Spread / Average Target
+8.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.37% | 1.92B | |
| +26.08% | 681B | |
| +21.85% | 556B | |
| -4.77% | 361B | |
| +16.97% | 325B | |
| +5.69% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Amneal Acquires Saol's Baclofen For $83.5 Million Plus Royalties
